Two-year data demonstrate continued high rates of primary patency including in patients with complex lesions LAS VEGAS and MARLBOROUGH, Mass., Oct. 5, 2021 /PRNewswire/ — Today, Boston Scientific (NYSE: BSX) announced positive results for the Ranger™ Drug-Coated Balloon (DCB) during a late-breaking clinical trial presentation at […]
Tag: Boston Scientific
Boston Scientific Announces Agreement to Acquire Devoro Medical, Inc.
Company to add mechanical thrombectomy platform to peripheral interventions portfolio MARLBOROUGH, Mass., Sept. 21, 2021 /PRNewswire/ — Today, Boston Scientific Corporation (NYSE: BSX) announced an agreement to acquire Devoro Medical, Inc., developer of the WOLF Thrombectomy® Platform. The innovative non-console and lytic-free WOLF technology targets […]
Boston Scientific Initiates Randomized Controlled Trial for the EkoSonic™ Endovascular System
Study is first to compare interventional therapy in combination with anticoagulation to anticoagulation alone for treatment of pulmonary embolism MARLBOROUGH, Mass., Aug. 4, 2021 /PRNewswire/ — Boston Scientific Corporation (NYSE: BSX) has commenced enrollment in the HI-PEITHO clinical trial, a collaborative research study […]
Boston Scientific Announces Results For Second Quarter 2021
MARLBOROUGH, Mass., July 27, 2021 /PRNewswire/ — Boston Scientific Corporation (NYSE: BSX) generated net sales of $3.077 billion during the second quarter of 2021, growing 53.6 percent on a reported basis, 49.6 percent on an operational1 basis and 52.4 percent on an organic2 basis, all compared to […]
Late-Breaking Trial Data at TVT Demonstrate Sustained Safety and Performance of WATCHMAN FLX™ Left Atrial Appendage Closure Device
PINNACLE FLX study meets 24-month endpoint, reinforces positive 12-month outcomes with next-generation device for patients with non-valvular atrial fibrillation MARLBOROUGH, Mass., July 21, 2021 /PRNewswire/ — Today, Boston Scientific (NYSE: BSX) announced positive 24-month results from the PINNACLE FLX clinical trial assessing the […]
Boston Scientific Exercises Option to Acquire Farapulse, Inc
Acquisition complements company’s electrophysiology portfolio to include the only commercially available cardiac pulsed field ablation technology MARLBOROUGH, Mass., June 24, 2021 /PRNewswire/ — Boston Scientific Corporation (NYSE: BSX) today announced it exercised its option to acquire the remaining shares of Farapulse, Inc. The acquisition […]
Late-Breaking Registry Data at EuroPCR Congress Demonstrate Reduced Paravalvular Leak and Low Permanent Pacemaker Rates for the ACURATE neo2™ Aortic Valve System
MARLBOROUGH, Mass., May 18, 2021 /PRNewswire/ — Data presented at hotline and late-breaking trial sessions today at the EuroPCR 2021 congress demonstrated positive procedural performance, including low rates of paravalvular leakage (PVL) and permanent pacemaker implementation (PPI), of the Boston Scientific (NYSE: BSX) ACURATE neo2™ Aortic […]
Boston Scientific Announces Results For First Quarter 2021
MARLBOROUGH, Mass., April 28, 2021 /PRNewswire/ — Boston Scientific Corporation (NYSE: BSX) generated net sales of $2.752 billion during the first quarter of 2021. This represents growth of 8.2 percent on a reported basis, 5.6 percent on an operational1 basis and 5.9 percent on an organic2 basis, all […]
Boston Scientific Announces Results For Fourth Quarter And Full Year 2020
MARLBOROUGH, Mass., Feb. 3, 2021 /PRNewswire/ — Boston Scientific Corporation (NYSE: BSX) generated net sales of $2.708 billion during the fourth quarter of 2020. This represents a decline of (6.8) percent on a reported basis, (8.3) percent on an operational1 basis and (8.0) percent on […]
Boston Scientific Announces Agreement To Acquire Preventice Solutions, Inc.
Acquisition of external cardiac monitoring technologies and services provider to expand rhythm management diagnostics portfolio and capabilities MARLBOROUGH, Mass., Jan. 21, 2021 /PRNewswire/ — Boston Scientific (NYSE: BSX) today announced that it has entered into a definitive agreement to acquire Preventice Solutions, Inc., a […]